Trial Profile

A Phase 2A Study of BMS-791325 in Combination With Peg Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Chronic Hepatitis C Virus Genotype 1 Infection.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Beclabuvir (Primary) ; Peginterferon alfa-2a; Ribavirin
Indications Hepatitis C
Focus Adverse reactions; Therapeutic Use
Acronyms HEPCAT
Sponsors Bristol-Myers Squibb

Most Recent Events

01 Oct 2013 Results will be presented at the 64th Annual Meeting of The American Association for the Study of Liver Diseases (AASLD) according to a Bristol-Myers Squibb media release.
04 Apr 2012 Results will be presented at EASL-2012 according to a Bristol-Myers Squibb media release.
18 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com